



**Coverage of any medical intervention discussed in a Medica medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and applicable state and/or federal laws.**

---

## **GENETIC TESTING: PREIMPLANTATION GENETIC TESTING**

**MP9574**

**Covered Service:** Yes

**Prior Authorization Required:** Yes. Dependent on applicable laws and provisions per state as outlined in the member benefit certificate or summary plan description.

**Additional Information:** Use the current applicable CPT/HCPCS code(s). An appropriate diagnosis code must appear on the claim. Claims will deny in the absence of applicable diagnosis and procedure code(s) and/or if the criteria for coverage outlined below are not met. The following codes are included below for informational purposes only, and may be subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.

Please see the member certificate or summary plan description for preimplantation genetic testing services available for coverage.

**Medica Medical Policy:**

## **OVERVIEW**

Preimplantation genetic testing involves analysis of biopsied cells from an embryo as a part of an assisted reproductive procedure. Preimplantation genetic testing for monogenic disorders (PGT-M) and preimplantation genetic testing for structural rearrangements (PGT-SR) are used to detect a specific inherited disorder in conjunction with in vitro fertilization (IVF) and aims to prevent the birth of affected children to couples at an increased risk of transmitting either a gene mutation(s) or an unbalanced structural chromosomal rearrangement that can be typically targeted in this context. Preimplantation genetic testing for aneuploidy (PGT-A) is used to screen for potential chromosomal or subchromosomal abnormalities (e.g., chromosomal aneuploidy) in conjunction with IVF for couples; in this case testing is untargeted.

## **POLICY REFERENCE TABLE**

The tests and associated laboratories and CPT codes contained within this document serve only as examples to help users navigate claims and corresponding coverage criteria; as such, they are not comprehensive and are not a guarantee of coverage or non-coverage. Please see the [Concert Genetics Platform](#) for a comprehensive list of registered tests.

**Coverage of any medical intervention discussed in a Medica medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and applicable state and/or federal laws.**

<a href="#">Coverage Criteria Sections</a>	Example Tests (Labs)	Common CPT Codes	Common ICD Codes	<a href="#">Ref</a>
<a href="#">Preimplantation Genetic Testing for Aneuploidy (PGT-A)</a>	Spectrum PGT-A (Natera)	81229, 81479, 89290, 89291	N97.0, N97.9, Z31	2, 3, 4
	SMART PGT-A (Preimplantation Genetic Testing - Aneuploidy) (Igenomix)	0254U		
<a href="#">Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)</a>	Spectrum PGT-M (Natera)	89290, 89291, 81479	N97.0, N97.9, Z14.8, Z31	1, 2
	PGT-M (Cooper Genomics)			
<a href="#">Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR)</a>	Preimplantation Genetic Testing for Structural Chromosomal Rearrangements/Translocations (Invitae)	81228, 81229, 81479, 89290, 89291	N97.0, N97.9, Z14.8, Z31	2
	Spectrum PGT-SR (Natera)			

## OTHER RELATED POLICIES

This policy document provides coverage criteria for preimplantation genetic testing. Please refer to:

- [Genetic Testing: Prenatal and Preconception Carrier Screening MP9575](#) for coverage criteria related to carrier screening.
- [Genetic Testing: Prenatal Diagnosis \(via amniocentesis, CVS, or PUBS\) and Pregnancy Loss MP9576](#) for coverage related to diagnostic genetic testing during pregnancy or for a pregnancy loss.
- [Genetic Testing: Noninvasive Prenatal Screening \(NIPS\) MP9573](#) for coverage criteria related to prenatal cell-free DNA screening tests.
- [Genetic Testing: Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay MP9587](#) for coverage criteria related to diagnostic genetic testing in the postnatal period.
- [Genetic Testing: General Approach to Genetic Testing MP9610](#) for coverage criteria related to preimplantation genetic testing that is not specifically discussed in this or another non-general policy.

Coverage of any medical intervention discussed in a Medica medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and applicable state and/or federal laws.

---

## COVERAGE CRITERIA

### PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A)

- 1.0 Preimplantation genetic testing for aneuploidy ([PGT-A](#)) (81229, 81479, 89290, 89291, 0254U) is considered **experimental and investigational**, and therefore not medically necessary.

[back to top](#)

### PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS (PGT-M)

Preimplantation genetic testing for monogenic disorders ([PGT-M](#)) (89290, 89291, 81479) may be considered **medically necessary** when:

- 2.1 The embryo is at an elevated risk of a genetic disorder due to **ONE** of the following:
- 2.1.1 Both biological parents are known carriers for the same autosomal recessive disorder, **OR**
  - 2.1.2 One biological parent is a known carrier of an autosomal dominant disorder, **OR**
  - 2.1.3 One biological parent is a known carrier of an X-linked recessive disorder.

- 3.0 Preimplantation genetic testing for monogenic disorders ([PGT-M](#)) (89290, 89291, 81479, 81403) is considered **experimental and investigational**, and therefore not medically necessary for all other indications.

[back to top](#)

### PREIMPLANTATION GENETIC TESTING FOR STRUCTURAL REARRANGEMENTS (PGT-SR)

- 4.0 Preimplantation genetic testing for structural rearrangements ([PGT-SR](#)) (81228, 81229, 89290, 89291, 81479) may be considered **medically necessary** when:

- 4.1 The embryo is at an elevated risk of a genetic disorder because one biological parent has a chromosomal rearrangement.

- 5.0 Preimplantation genetic testing for structural rearrangements ([PGT-SR](#)) (81228, 81229, 89290, 89291, 81479) is considered **experimental and investigational**, and therefore not medically necessary for all other indications.

[back to top](#)

## NOTES AND DEFINITIONS

1. Close relatives include first, second, and third degree blood relatives on the same side of the family:

**Coverage of any medical intervention discussed in a Medica medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and applicable state and/or federal laws.**

---

- a. **First-degree relatives** are parents, siblings, and children
  - b. **Second-degree relatives** are grandparents, aunts, uncles, nieces, nephews, grandchildren, and half siblings
  - c. **Third-degree relatives** are great grandparents, great aunts, great uncles, great grandchildren, and first cousins
2. Preimplantation genetic testing for monogenic disorders (**PGT-M**) and Preimplantation genetic testing for structural rearrangements (**PGT-SR**) are used to detect a specific single-gene inherited disorder or chromosome rearrangement in conjunction with in vitro fertilization (IVF)
  3. Preimplantation genetic testing for aneuploidy (**PGT-A**) is used to screen for chromosomal aneuploidy in conjunction with IVF for couples.

[back to top](#)

## CLINICAL CONSIDERATIONS

Genetic counseling is highly encouraged for patients considering and undergoing in vitro fertilization. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods, such as a genetic counselor, medical geneticist, or advanced practice practitioner specializing in genetics.

All patients who undergo PGT-M or PGT-SR should be offered diagnostic testing via chorionic villus sampling (CVS) or amniocentesis for confirmation of results.

All patients who undergo PGT-A should be offered traditional diagnostic testing or screening for aneuploidy in accordance with recommendations for all pregnant patients.

[back to top](#)

## BACKGROUND AND RATIONALE

### Preimplantation Genetic Testing for Aneuploidy (PGT-A)

*American Society of Reproductive Medicine*

The American Society for Reproductive Medicine issued an opinion on the use of preimplantation genetic testing (PGS) for aneuploidy (2018) which concluded, "Large, prospective, well-controlled studies evaluating the combination of multiple approaches (genomics, time-lapse imaging, transcriptomics, proteomics, metabolomics, etc.) for enhanced embryo selection applicable in a more inclusive IVF population are needed to determine not only the effectiveness, but also the safety and potential risks of these technologies. PGT-A will likely be part of a future multidimensional approach to embryo screening and selection. At present, however, there is insufficient evidence to recommend the routine use of blastocyst biopsy with aneuploidy testing in all infertile patients." (p. 34)

**Coverage of any medical intervention discussed in a Medica medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and applicable state and/or federal laws.**

---

This position was reaffirmed in a 2020 committee opinion regarding clinical management of mosaic results from preimplantation genetic testing for aneuploidy of blastocysts, stating, "It should be recognized that this document does not endorse nor does it suggest that PGT-A is appropriate for all cases of IVF." (p. 253)

*American College of Obstetricians and Gynecologists (ACOG)*

The American College of Obstetricians and Gynecologists issued Committee Opinion No. 799 (2020) regarding Preimplantation Genetic Testing. The recommendations include the following:

"The clinical utility of preimplantation genetic testing-monogenic and preimplantation genetic testing-structural rearrangements is firmly established; however, the best use of preimplantation genetic testing-aneuploidy remains to be determined." (p. e133)

**Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)**

*American Society for Reproductive Medicine*

The American Society for Reproductive Medicine published an opinion on the use of preimplantation genetic diagnosis (PGD) for serious adult-onset conditions (2013). The statement includes the following:

- "Preimplantation genetic diagnosis (PGD) for adult-onset conditions is ethically justifiable when the conditions are serious and when there are no known interventions for the conditions or the available interventions are either inadequately effective or significantly burdensome."
- "For conditions that are less serious or of lower penetrance, PGD for adult[-]onset conditions is ethically acceptable as a matter of reproductive liberty. It should be discouraged, however, if the risks of PGD are found to be more than merely speculative."

The opinion also stated that physicians and patients should be aware that much remains unknown about the long-term effects of embryo biopsy on the developing fetus and that experienced genetic counselors should be involved in the decision process. (p. 54)

*American College of Obstetricians and Gynecologists (ACOG)*

The American College of Obstetricians and Gynecologists issued Committee Opinion No. 799 (2020) regarding Preimplantation Genetic Testing. The recommendations include the following:

"Preimplantation genetic testing comprises a group of genetic assays used to evaluate embryos before transfer to the uterus. Preimplantation genetic testing-monogenic (known as PGT-M) is targeted to single gene disorders. Preimplantation genetic testing-monogenic uses only a few cells from the early embryo, usually at the blastocyst stage, and misdiagnosis is possible but rare with modern techniques. Confirmation of preimplantation genetic testing-monogenic results with chorionic villus sampling (CVS) or amniocentesis should be offered." (p. 133).

**Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR)**

**Coverage of any medical intervention discussed in a Medica medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and applicable state and/or federal laws.**

---

*American College of Obstetricians and Gynecologists (ACOG)*

The American College of Obstetricians and Gynecologists issued Committee Opinion No. 799 (2020) regarding Preimplantation Genetic Testing. The recommendations include the following: "To detect structural chromosomal abnormalities such as translocations, preimplantation genetic testing-structural rearrangements (known as PGT-SR) is used. Confirmation of preimplantation genetic testing-structural rearrangements results with CVS or amniocentesis should be offered." (p. 133)

[back to top](#)

## REFERENCES

1. Ethics Committee of American Society for Reproductive Medicine. Use of preimplantation genetic diagnosis for serious adult onset conditions: a committee opinion. *Fertil Steril*. 2013;100(1):54-57. doi:10.1016/j.fertnstert.2013.02.043
2. Preimplantation Genetic Testing: ACOG Committee Opinion, Number 799. *Obstet Gynecol*. 2020;135(3):e133-e137. doi:10.1097/AOG.0000000000003714
3. Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Electronic address: ASRM@asrm.org; Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion. *Fertil Steril*. 2018;109(3):429-436. doi:10.1016/j.fertnstert.2018.01.002
4. Practice Committee and Genetic Counseling Professional Group (GCPG) of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Clinical management of mosaic results from preimplantation genetic testing for aneuploidy (PGT-A) of blastocysts: a committee opinion. *Fertil Steril*. 2020;114(2):246-254. doi:10.1016/j.fertnstert.2020.05.014

[back to top](#)



**Coverage of any medical intervention discussed in a Medica medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or summary plan description (SPD) and applicable state and/or federal laws.**

---

	Committee/Source	Date(s)
<b>Document</b>		
<b>Created:</b>	Medical Policy Committee/Health Services Division	October 19, 2022
<b>Revised:</b>	Medical Policy Committee/Health Services Division	November 16, 2022
	Medical Policy Committee/Health Services Division	March 15, 2023
	Medical Policy Committee/Health Services Division	August 16, 2023
<b>Reviewed:</b>	Medical Policy Committee/Health Services Division	November 16, 2022
	Medical Policy Committee/Health Services Division	March 15, 2023
	Medical Policy Committee/Health Services Division	August 16, 2023

Published: 01/01/2024

Effective: 01/01/2024